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Abstract
Background: Tyrosine hydroxylase (TH) regulates dopamine (DA) bioavailability. Its product, L-DOPA, is an established
treatment for Parkinson’s disease (PD), suggesting that TH regulation influences locomotion. Site-specific phosphorylation
of TH at ser31 and ser40 regulates activity. No direct evidence shows that ser40 phosphorylation is the dominating
mechanism of regulating TH activity in vivo, and physiologically-relevant stimuli increase L-DOPA biosynthesis independent
of ser40 phosphorylation. Significant loss of locomotor activity occurs in aging as in PD, despite less loss of striatal DA or TH
in aging compared to the loss associated with symptomatic PD. However, in the substantia nigra (SN), there is equivalent
loss of DA or TH in aging and at the onset of PD symptoms. Growth factors increase locomotor activity in both PD and aging
models and increase DA bioavailability and ser31 TH phosphorylation in SN, suggesting that ser31 TH phosphorylation
status in the SN, not striatum, regulates DA bioavailability necessary for locomotor activity.
Methodology and Principal Findings: We longitudinally characterized locomotor activity in young and older Brown-
Norway Fischer 344 F1 hybrid rats (18 months apart in age) at two time periods, eight months apart. The aged group served
as an intact and pharmacologically-naı ¨ve source of deficient locomotor activity. Following locomotor testing, we analyzed
DA tissue content, TH protein, and TH phosphorylation in striatum, SN, nucleus accumbens, and VTA. Levels of TH protein
combined with ser31 phosphorylation alone reflected inherent differences in DA levels among the four regions. Measures
strictly pertaining to locomotor activity initiation significantly correlated to DA content only in the SN. Nigral TH protein and
ser31 phosphorylation together significantly correlated to test subject’s maximum movement number, horizontal activity,
and duration.
Conclusions/Significance: Together, these results show ser31 TH phosphorylation regulates DA bioavailability in intact
neuropil, its status in the SN may regulate locomotor activity generation, and it may represent an accurate target for
treating locomotor deficiency. They also show that neurotransmitter regulation in cell body regions can mediate behavioral
outcomes and that ser31 TH phosphorylation plays a role in behaviors dependent upon catecholamines, such as dopamine.
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Introduction
We face an increased probability of reduced mobility (bradyki-
nesia) with advancing age, with a 50% risk of this Parkinsonian-like
symptom by age 85 [1,2]. The neurobiological basis of this aging-
related impairment to locomotion is crucial to resolve, particularly
due to the imminent increase of the elderly population. Aging-
related Parkinsonism presents symptoms similar to Parkinson’s
disease (PD) and, like PD, they are progressive, impair performance
of essential locomotor functions, and increase risk of cognitive
impairment, dementia, and death [2–5]. Major dopamine (DA) loss
of 70–80% in the striatum is thought to be required for major
symptom presentation inPD [6–10]. However, in aged humans and
animal models alike, striatal DA loss does not reach symptomatic
levels seen in PD, ranging instead from 0 to 50% [11–15].
Throughout the lifespan there is also little if anyaging-related loss of
striatal tyrosine hydroxylase ((TH), the rate-limiting enzyme for DA
biosynthesis) [15–20], which is in stark contrast to the 80% loss seen
in symptomatic PD [6,8]. Thus, it is curious why aging-related
Parkinsonism occurs if DA and TH loss are not equivalent to the
symptomatic levels seen in PD.If TH loss does not occur in striatum
during aging, it is possible that either decreased striatal TH activity
may contribute to Parkinsonism, or decreased TH protein or
activity in another DA region is the source of Parkinsonism.
The activity of TH is regulated by site-specific phosphorylation,
but of the three physiologically-regulated sites in the CNS (ser19,
ser31, and ser40) [21], the site most critical for regulating DA
biosynthesis in intact neuropil is unknown. Phosphorylation of TH
at ser19 does not directly influence TH activity [22], but increased
phosphorylation of ser40 can increase TH activity [23–26] and is
associated with increased DA turnover in neurodegenerative or
other CNS disorders [27,28]. However, a certain threshold of
phosphorylation may be required to affect DA biosynthesis [25]
and ser40 phosphorylation is not required for stimulation of L-
DOPA biosynthesis by depolarizing stimuli [29]. However,
increases in ser31 phosphorylation alone increase L-DOPA
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ser40 phosphorylation modulate DA bioavailability in intact
neuropil is necessary to define the molecular basis for DA-
dependent behaviors, such as locomotion.
WhilelossofTHactivitymayexplainvariableDAlossinthe aged
striatum, it is also possible that aging reduces TH protein or activity,
and therefore DA bioavailability, in other regions affecting
locomotor activity. For example DA signaling in the nucleus
accumbens (NAc) affects goal-related locomotor activity [30] as it
does in striatum [31]. However, stimulant-induced increases in DA
signaling in NAc are similar between aged and young subjects and
thus do not explain reduced stimulant-induced locomotion in aged
subjects [32]. A potential explaination is that an intact nigrostriatal
pathway may be necessary for stimulant enhancement of locomotor
activity [33]. In this pathway, dopamine is released not only in
striatum, but also in the substantia nigra (SN) [34,35]. Although
striatal DA tissue content is ,10-fold greater than in SN [12,13],
DA in SN has a longer synaptic life than in striatum [36,37].
Notably, unlike striatum, aging reduces TH protein in SN and this
correlates with motor impairment [38]. Thus TH regulation of DA
intheSNmayaffectcertainaspectsoflocomotoractivitygeneration.
In fact, decreasing nigral DA release capacity [39] or blocking its
post-synaptic actions [40,41] reduces locomotor activity. Bradyki-
nesia is a common symptom of PD and aging. Similar deficiencies in
nigral DA signaling as well as reduced TH protein reported with the
onset of PD symptoms [10,42] and in aging [18,38,43] also point to
the possibility that nigral DA bioavailability regulates locomotor
activity generation. Aging also reduces nigral TH activity [44], and
DA loss ranges from 36%–70% in human [45], non-human
primates [17], and rat [13]. Thus, deficits in TH protein and
phosphorylation at the key TH activity-modulating site in SN could
be the common source of bradykinesia in PD and in aging.
Studies with growth factors indicate that nigral TH activity may
regulate locomotor activity. GDNF increases locomotor activity in
both aging or PD models in conjunction with increased nigral DA
tissue content, notably without affecting striatal DA tissue content
[46–49]. In aged rats, GDNF produces a large increase in ser31
phosphorylation in the SN [50], suggesting that the action of
GDNF is to reverse possible aging-related reductions in nigral
ser31 phosphorylation, thereby increasing nigral DA and locomo-
tor activity as reported. Furthermore, unilateral striatal GDNF
administration increases TH phosphorylation bilaterally only in
the SN and not striatum [51]. This may also occur in human, as
bilateral motor improvement is reported following unilateral
GDNF delivery in PD patients [52]. Taken together, we
hypothesized that ser31 phosphorylation of TH in SN may
regulate DA bioavailability necessary for particular aspects of
locomotor activity. To test this hypothesis we profiled DA tissue
content and TH protein and phosphorylation in the nigrostriatal
and mesoaccumbens pathways in young and aged rats following
longitudinal characterization of inherent locomotor activity. This
design, while correlational, provided an intact and pharmacolog-
ically-naı ¨ve source of potential endogenous differences in DA
bioavailability in DA neuropil in two groups significantly different
in locomotor activity to address which TH phosphorylation site
normally regulates DA bioavailability and which DA region
influences specific aspects of inherent locomotor activity.
Methods
2.1 Test Subject Selection and Handling
Young and old rats were chosen for this study because differences
in locomotor activity are derived from intact and pharmacological-
ly-naı ¨ve neuropil. Two age groups of Brown-Norway Fisher 344 F1
hybrid (BNF) rats arrived at the medical center at one and 19
months of age and given food and water ad libitum for three months
prior to the start of any locomotor assessment. All locomotor testing
was done between the hours of 0900 and 1700. All animals used in
thisstudyweredrugnaı ¨veand otherthanbeingtestedforlocomotor
activity 17 times for one hour each session, remained in their home
cage, singly housed. The BNF strain was selected for this study
because aging-related changes in striatal and midbrain DA tissue
content are comparable to that in the primates and exhibits reduced
locomotion in aging ([13,53], and as discussed in main text), making
it arguably the best rat model to address the relative role of the
striatal and nigral DA in locomotor activity. Outbred Sprague-
Dawley rats also show DA loss in the midbrain like the BNF strain
[54] but may have increased variance in a variety of measures. The
inbred Fischer 344, a commonly used strain in aging studies, does
not show any significant tissue loss of DA in striatum or midbrain,
contrary to findings in human and non-human primates (although
release of DA is compromised 50% [12]). In general, F1 hybrids
have less variability in a large number of physiological and
behavioral measures, including locomotor functions [55]. This
reduction in variance in F1 hybrids requires fewer animals to attain
significance [56].
2.2 Assessment of Locomotor Activity
Open-field locomotor activity was determined a total of 17
times in two specific time points, the young being tested at 4–5
months and again eight months later at 11–12 months, and the
older group at 22–23 months of age and again eight months later
at 29–30 months of age. [Neurochemical measures were made
only at the 12 and 30 month ages]. Each rat was tested by pairing
with the same different age counterpart in separate locomotor test
chambers (10 trials in the first period of life and 7 trials in the
second period of life eight months later). Spontaneous locomotor
activity was assessed in 1 hour duration trials using automated
activity chambers (VersaMax Animal Activity Monitoring System,
Columbus, OH), which consisted of a 41641631 cm
3 plexiglass
box with a grid of infrared beams mounted horizontally every
2.5 cm and vertically every 4.5 cm. The beams are generated
from monitors connected to a VersaMax analyzer which transmits
the number of beam breaks (locomotor activity) to a dedicated
computer with VersaMax software to collect and analyze the
locomotor measures. Activity data was recorded in four consec-
utive 15 min samples and the sum total for movement number,
total distance (cm), horizontal activity (unitless measure of all
horizontal activity), time spent moving (sec) were recorded.
Movement speed was calculated by dividing total distance by
time spent moving (cm/sec). The typical life-expectancy of the
BNF rat is approximately 32 months and thus, the locomotor
activities in about one-fourth to one-third of the average life span
of the rat were determined for each age group. Combining both
operationally-matched age groups, the locomotor activity patterns
of virtually the entire adult life span was determined.
To assess DA tissue content and TH protein and phosphory-
lation, within 5–10 min following the last (17
th) locomotor test
session, the rats were killed in alternating order of young or old,
and dorsal striatum, substantia nigra, nucleus accumbens, and
VTA were dissected from 1 mm coronal slices as previously
described [57] and stored on dry ice and 270uC until processed
for DA analysis by HPLC, protein levels, and phosphorylation
analysis by western blotting.
2.3 Neurochemistry: Dopamine Analysis
The analysis of DA tissue content from striatum, SN, NAc, and
VTA allowed for two major objectives to be addressed; 1) to
Dopamine and Locomotion
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capacity in the CNS, and 2) to correlate to measures of locomotor
activity with DA tissue content in these four regions. Given the well-
established DA hypothesis for locomotion, this experimental design
makes it possible to determine whether DA in one or more of these
regions influenced locomotion. Our operationally-matched assess-
ment of DA tissue content and TH measures from all four brain
regions from each test subject is a novel state-of-the-art approach to
equate the DA tissue content resulting from a respective TH protein
and TH phosphorylation profile and to determine their contribu-
tions to locomotor activity. This addition of locomotor measures to
the neurochemical profile is the first known study of its kind, which
adds a behavioral component in assessing DA tissue content with
TH protein and TH phosphorylation [27].
Tissues were sonicated in ice-cold 0.1 M HClO4-EDTA buffer.
Aliquots from these protein-precipitated supernatants were
analyzed for content of DA by HPLC [58]. Determination of
DA is calculated based upon percent recovery of the internal
standard (N-methyl-dopamine (NMDA), 20 ng/mL) in each
sample, the peak height ratios obtained for both DA and NMDA
in a standard and in the sample, and the fraction of the aliquot
analyzed by HPLC representing the total volume of the sonicated
tissue. The acid buffer treatment for HPLC analysis precipitates
the protein content inherent in the sample, and this protein pellet
was sonicated in 1% SDS with 5 mM Tris buffer (pH 8.3) and
1 mM EDTA to determine total protein, TH protein, and site-
specific TH phosphorylation.
We normalized total DA to protein, as opposed to the wet
weight of tissue. This was done to control for variances that can
arise from contributions of non-protein material. However, this
normalization also requires precision dissections for each test
subject along the rostral-caudal axis, as the inadvertent additions
of non-DA cells in the dissection would increase protein content
not related to DA neuropil. For this reason, we present the DA
measures as per total DA harvested and as total DA normalized to
mg protein. These results were similar (Table 1) and had
significant correlation with each other (data not shown).
Furthermore, our additional normalization of total DA to total
TH harvested in the sample is the strictest normalization to DA
neuropil and gives the best insight into endogenous TH activity.
2.4 Neurochemistry: Determination of TH Protein and
Phosphorylation
Protein levels were determined by BCA method and samples
were prepared in reducing (dithiothreitol used as reducing agent)
sample buffer containing SDS and subjected to SDS gel
electrophoresis on 10% gels, and transferred to nitrocellulose.
Protein loads were verified by Ponceau S stain and blots were
preincubated with polyvinylpyrrolidone-based Tris buffer for at
least 2 hr prior to antibody exposure to reduce non-specific
binding. For each blot immunolabeling experiment, after
treatment with primary and secondary antibody (for signal
enhancement), the detection method used I
125-protein A (high-
specific activity). The blots were exposed to Kodak film which
reveals immunoreactive areas on the blot. These areas were
excised and counted for gamma radioactivity. To quantify total
TH, in house standards (calibrated PC12 cell extract) are used to
interpolate sample immunoreactivity to anti-TH versus a standard
curve of known quantities of TH and the value is expressed as ng
TH per ug total protein loaded [25,27,50,51,57].
Protein phosphorylation is quantified by western blot using
affinity-purified primary antibodies specific to each phosphoryla-
tion site. We used our own affinity-purified ser31 phosphorylation
primary (21
st Century Biochemicals), and ser19 and ser40
antibodies were a gift from Dr. John W. Haycock. The ser31
primary antibody was validated for phosphorylation-state speci-
ficity (Fig. S1, Text S1). Calibrated phosphorylation site-specific in
house standards are used to quantify phosphorylation levels and
are normalized to the TH content to determine the phosphory-
lation stoichiometry, as previously reported [25,27,50,51,57].
Assays for TH protein and its site-specific phosphorylation are
conducted within the dynamic working range of each antibody.
2.5 Statistics
Analysis of locomotor profiles. Locomotor activity was
analyzed in five parameters. Four parameters (movement number,
Table 1. p-values of locomotor functions versus DA tissue
content.
nigrostriatal
Striatum SN
Parameter variable DA DA/prot DA DA/prot
Movement
number
Lifetime avg 0.66 0.48 0.008 0.028
Session 2 0.83 0.59 0.005 0.042
Highest lifetime 0.94 0.43 0.004 0.011
Lowest lifetime 0.51 0.35 0.007 0.010
Last trial 0.42 0.28 0.011 0.012
Total distance Lifetime avg 0.35 0.32 0.026 0.012
Session 2 0.36 0.68 0.035 0.024
Highest lifetime 0.97 0.99 0.009 0.017
Lowest lifetime 0.24 0.41 0.031 0.042
Last trial 0.38 0.62 0.15 0.034
Horizontal
activity
Lifetime avg 0.58 0.56 0.004 0.016
Session 2 0.78 0.90 0.003 0.038
Highest lifetime 0.94 0.74 0.002 0.016
Lowest lifetime 0.59 0.42 0.07 0.15
Last trial 0.52 0.46 0.007 0.005
Time spent
moving
Lifetime avg 0.42 0.41 0.013 0.010
Session 2 0.93 0.75 0.011 0.038
Highest lifetime 0.94 0.70 0.002 0.010
Lowest lifetime 0.27 0.31 0.019 0.029
Last trial 0.42 0.51 0.026 0.012
Movement
speed
Lifetime avg 0.06 0.95 0.44 0.047
Session 2 0.055 0.73 0.60 0.065
Highest lifetime 0.76 0.25 0.54 0.58
Lowest lifetime 0.56 0.33 0.26 0.19
Last trial 0.67 0.12 0.051 0.46
Correlation statistics (p-values derived from Spearman correlation) of locomotor
activity measures to respective DA tissue content (total ng or total ng per
protein) in striatum and SN analyzed in 7 paired 12- and 30-month old rats.
Activity measures are further subdivided into the lifetime average (mean of 17
total locomotor trials conducted at 4 and 12 months for the young group and
22 and 30 months for the old group), session 2 (mean of seven locomotor trials
that were conducted at 12 and 30 months), highest and lowest lifetime (highest
ever, and lowest ever, locomotor activity measures of the 17 sessions), and last
trial (the final locomotor activity measure of the 17, recorded immediately prior
to tissue dissection). Significant correlations are in bold.
doi:10.1371/journal.pone.0008466.t001
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recorded with software as previously described and movement
speed was calculated as total distance divided by time spent
moving. Aging related comparisons were analyzed by ANOVA
followed by Bonferroni’s multiple comparison test between the age
groups and also a Student’s t-test was used for within age-group
comparisons (4 vs. 12 months, 22 vs. 30 months). Correlations
between dependent measures used the Spearman correlation
coefficient, including correlations of locomotor activity with DA
measures, as shown in table 1. The five parameters of locomotor
activity for each test subject were also analyzed in five ways
(lifetime average, average of second session of seven trials, highest
lifetime trial result, lowest lifetime trial result, and the last (17
th)
trial.
Analysis of neurochemical profiles. Dopamine tissue
content was analyzed three ways; 1) total DA recovered per
region, 2) total DA recovered per total protein, 3) total DA
recovered per total TH. The respective tissue content of DA in the
four regions are considered treatments for the purpose of
determining the influence of TH protein and site-specific
phosphorylation upon DA tissue content. The role of site-specific
phosphorylation upon DA tissue content was determined by
normalizing inherent DA to TH protein and comparing
differences in site-specific phosphorylation to the differences in
DA per TH protein in each region (ANOVA followed by
Bonferroni’s multiple comparison test). We also compared total
DA harvested in each region with total TH protein harvested to
show how TH protein alone contributes but does not fully account
for the regional differences in DA.
Results
3.1 Molecular Origin of DA Bioavailability
Although phosphorylation of TH by ERK at ser31 or PKA at
ser40 can increase DA biosynthesis in situ [25,26], which
phosphorylation site affects DA bioavailability in intact neuropil
is unknown. As would be predicted, though not yet shown in vivo,
total TH protein content in the SN correlated to total DA
recovered in each test subject (p,0.05, Fig. S2) and significant
correlations were also seen in the other three regions (data not
shown). However, relative differences in DA tissue content among
the four regions (Fig. 1a) were not matched by TH content in these
tissues (Fig. 1b) [note that actual values are indicated in figure
legend to support this finding], signifying that site-specific
phosphorylation also contributes to regulating inherent DA tissue
content in the CNS. Normalizing DA tissue content to total TH
recovered in each region removes the influence of total TH on DA
content (Fig. 1c). Therefore, the phosphorylation site regulating
TH activity in vivo in intact neuropil would be predicted to vary
across all four regions in a pattern similar to the differences in TH-
normalized DA content. The differences in ser31 phosphorylation
stoichiometry (Fig. 1d) reflected these differences in TH-normal-
ized DA content, whereas ser40 (Fig. 1e) and ser19 (Fig. 1f)
phosphorylation stoichiometry did not reflect these differences.
Total TH protein also affected total DA content in conjunction
with ser31 phosphorylation. Total DA recovered from the four
tissues was greatest in the striatum, followed by the nucleus
accumbens ((NAc) ,3.5-fold less than striatum), and comparable
amounts in the SN and VTA (Fig. 1a). Recovery of DA in the NAc
was nearly seven-fold greater than in SN (Fig. 1a) despite relatively
equal recovery of TH protein between the NAc and SN (68 and
59 ng total TH, respectively (Fig. 1b)), and this difference was
explained by ,four-fold greater ser31 phosphorylation stoichiom-
etry (Fig. 1d) in the NAc compared to SN (p,0.001, Fig. 1d),
whereas ser19 or ser40 phosphorylation stoichiometry was not
significantly different between the two regions (Figs. 1e, 1f).
However, total DA recovery in striatum was 3.5-fold greater than
in the NAc (Fig. 1a), in spite of similar levels of ser31
phosphorylation stoichiometry (Fig. 1d). Between these regions it
appears that the 3- to 4-fold greater level of TH protein in striatum
compared to NAc (Fig. 1b) influenced their inherent differences in
DA.
These data show that both TH protein levels and phosphor-
ylation at ser31 in intact CNS tissue affect DA tissue content.
Thus, multiplying the total TH protein content by TH
phosphorylation stoichiometry (effective stoichiometry) at the key
regulatory phosphorylation site should represent inherent DA
biosynthesis capabilities in DA neuropil. The effective stoichiom-
etry at ser31 should, therefore, reflect the differences in DA
content across each region. Indeed, the effective stoichiometry for
ser31 (Fig. 2a), unlike ser40 or ser19 (Fig. 2b, 2c), had similar
region-to-region variance as compared to differences in total DA
content (Fig. 1a). Notably, this is apparent in comparing striatum
to SN, as there was a 25-fold greater level of DA in striatum
(Fig. 1a) and a nearly identical 24-fold difference in effective
stoichiometry at ser31 (eight-fold greater TH protein (Fig. 1b)
times three-fold greater ser31 phosphorylation stoichiometry
(Fig. 1d)). The effective stoichiometry at ser40 (Fig. 2b) was only
four-fold different between striatum and SN and was not
significantly different between SN and nucleus accumbens and
as such did not reflect the differences in DA tissue content
recovered (Fig. 1a). These observations clearly show that ser31
phosphorylation, in conjunction with TH protein content,
regulates DA bioavailability in the intact nigrostriatal and
mesoaccumbens dopaminergic neuropil. In terms of behavioral
significance, these findings suggest that ser31 phosphorylation
status may drive DA-dependent behaviors from neuroanatomical
loci associated with such behaviors.
3.2 Locomotor Profiling and Regional Dopamine
Bioavailability Correlations
Prior to neurochemical analyses, the test subjects, seven young
and seven old BNF rats (groups differing in age by 18 months),
were characterized for open-field locomotor activity, independent
of exogenous influences such as systemically- or CNS-delivered
drugs, in a longitudinal study. There were ten trials conducted
when the young group was 4 months old and the old group was 22
months old, and another seven trials conducted when the young
group was 12 months old and the old group was 30 months old.
The paucity of initiated movement is a signature behavioral
symptom of bradykinesia, and as such, movement number,
horizontal activity, and time spent moving are three locomotor
activity measures arguably the closest to quantifying bradykinesia.
Notably, movement number had significant correlation with all
other measures of locomotor activity at all ages of testing, with the
exception of movement speed, (Fig. S3). The repetitive nature of
the locomotor activity measures did not produce a significant
decrease in locomotor activity in the majority of the test subjects
(Table S1) in either testing session, so habituation was not a
confounding effect on mean locomotor results.
Because there was only one opportunity to assess DA tissue
content along with TH protein and TH phosphorylation, we
compared the locomotor activity results in five time-related
measures; lifetime average (mean of 17 total locomotor trials
conducted at 4 and 12 months for the young group and 22 and 30
months for the old group), session 2 (mean of seven locomotor trials
conducted at 12 and 30 months), highest and lowest lifetime (highest
ever, and lowest ever, locomotor activity measures of the 17
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8466Figure 1. Dopamine, tyrosine hydroxylase protein, and phosphorylation stoichiometry (ps) comparisons in nigrostriatal and
mesoaccumbens pathways. Analyses of striatum (str), substantia nigra (SN), nucleus accumbens (NAc), and ventral tegmental area (VTA) from all
test subjects (n=14, seven pairs of 12 and 30 month old rats from locomotor study). a. total DA recovery The mean relative total recovery of DA (in
ng) was Str=214616; SN=8.460.8; NAc= 59.665.8; VTA=6.061.0. b. total TH protein recovery The mean TH recovery (in ng) was Str=473649;
SN=5969; NAc=6869; VTA=2665. c. TH-Normalized DA tissue content Str 0.5660.11, SN 0.1860.03, NAc 0.7760.03, VTA 0.2260.03. There
was a significant difference in DA recovered per TH among the four regions (ANOVA (p,0.0001) and between Str and SN (p,0.001), Str and VTA
(p,0.01), SN and NAc (p,0.001), and VTA and NAc (p,0.001). d. ser31 phosphorylation stoichiometry (PS) Str 0.3360.02, SN 0.0960.01, NAc
0.3660.01, VTA 0.1060.01. There was a significant difference in ser31 phosphorylation among the four regions (ANOVA (p,0.0001) and between Str
and SN (p,0.001), Str and VTA (p,0.001), SN and NAc (p,0.001), and VTA and NAc (p,0.001). e. ser40 PS Str 0.02260.001, SN 0.04560.004, NAc
0.04960.004, VTA 0.03560.002. There was a significant difference in ser40 phosphorylation among the four regions (ANOVA (p,0.0001) and
between Str and SN (p,0.001), Str and NAc (p,0.001), Str and VTA (p,0.05), and NAc and VTA (p,0.05). f. ser19 PS Str 0.0660.01, SN 0.1360.01,
NAc 0.1260.01, VTA 0.2560.01. There was a significant difference in ser19 phosphorylation among the four regions (ANOVA (p,0.0001) and between
Str and SN (p,0.001), Str and NAc (p,0.01), Str and VTA (p,0.001), SN and VTA (p,0.001) and NAc and VTA (p,0.001).
doi:10.1371/journal.pone.0008466.g001
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17, recorded immediately prior to tissue dissection) (Table 1).
Total DA tissue content from the SN, but not striatum, NAc, or
VTA (NAc and VTA data in Table S2), correlated significantly
with four of five locomotor parameters, the notable exception
being movement speed (Fig. 3, Table 1), and for each time-related
comparison. Striatal DA did not correlate with any locomotor
parameter, but there was a noted trend with the lifetime average
and session 2 movement speed (Table 1). This lack of correlation
may be related to the small insignificant aging-related loss of
striatal or accumbal DA.
3.3 Relative Individual Locomotor Activities Are
Maintained but Decline with Aging
Consistent with the literature, significant aging-related decreases
occurred in all locomotor measures with the exception of
movement speed. Movement number, horizontal activity, time
spent moving, (Fig. 4a–c), and total distance traveled (data not
shown) decreased significantly between the age groups (ANOVA,
p,0.0001). Importantly, there was a significant group difference
between the two age groups at 12 and 30 months (p,0.05), the
ages at which neurochemical profiles were obtained. There was a
significant difference at 4 and 22 months as well (p,0.001,
Bonferroni’s multiple comparison test), broaching the possibility of
an inherent molecular basis for locomotor activity. The significant
group differences in locomotor activity, in addition to the
variances seen within groups, gave a range of inherent differences
in locomotor activity to address this possibility.
While there was an aging-related decline in locomotor activity
(Fig. 4), individual test subjects had consistent locomotor activity
levels in relation to the other test subjects between the eight months
of locomotor trials, suggesting that there is a neurobiological basis
for locomotion maintained with respect to the group, though
declining, in each individual with advancing age. There was a
significant correlation for movement number, horizontal activity,
time spent moving (Fig. 5a–c), total distance and movement speed
(data not shown) between the first and second test sessions. Thus
comparisons of DA and TH measures to inherent lifetime
locomotor patterns of test subjects could reveal how TH regulates
DA bioavailability and inherent locomotor activity.
3.4 Aging, Population Variance, and a Dopaminergic Basis
Aged rats have an inherent decrease in locomotor activity and
provide intact neuropil to compare where DA bioavailability
Figure 2. Tyrosine hydroxylase effective stoichiometry in nigrostriatal and mesoaccumbens pathways. Values are obtained by
multiplying total inherent TH protein content by phosphorylation stoichiometry in each sample. a. Ser31 es. Stoichiometry determined by anti-
phospho ser31 TH against calibrated standards for ser31 and divided by total TH protein. b. Ser40 es c. ser19 es Values were calculated based
upon each subject’s ps value and multiplied by the mean total TH. Region-to-region difference for ser31 es was similar to the difference in total DA
(as shown in Fig. 1a) recovered from the longitudinally-characterized inherent locomotor activity patterns for the test subjects.
doi:10.1371/journal.pone.0008466.g002
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8466Figure 3. Dopamine bioavailability and correlation to locomotor activity generation. Total DA in striatum ((str) a, c, e) versus substantia
nigra ((SN) b, d, f) and correlation to mean lifetime locomotor activity measures in all 14 subjects, ages 12 and 30 months (n=7 each age group). The
following are the Spearman correlation values and p-values; Movement number, a. str, p=0.65, r=0.13 b. SN,* * p=0.008, r=0.68, Horizontal
activity, c. str, p=0.58, r=0.16 d. SN,* * p=0.008, r=0.72; Time spent moving, e. str, p=0.42, r=0.24 e. SN,* p=0.01, r=0.64. Additional
statistical correlations are presented in Table 1.
doi:10.1371/journal.pone.0008466.g003
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8466Figure 4. Longitudinal-characterization of locomotor activity
during aging. Mean for the age tested represented by horizontal line
and the locomotor activities of test subjects represented by points. The
young group was tested at 4 and 12 months and the old group tested
at 22 and 30 months. a. movement number (ANOVA, group p,0.0001;
post-hoc 12 vs. 30 mos, p,0.05): aging difference within group, 4 vs.
12 mos., p,0.05; 22 vs. 30 mos., p,0.05 (Student’s paired t-test used
for all within group comparisons). b. horizontal activity (ANOVA, group
p,0.0001; post-hoc 12 vs. 30 mos., p,0.01): aging difference within
group, 4 vs. 12 mos., p,0.05; 22 vs. 30 mos., p,0.05. c. time spent
moving (ANOVA, group p,0.0001; post-hoc 12 vs. 30 mos., p,0.05):
aging difference within group, 4 vs. 12 mos., p,0.05; 22 vs. 30 mos.,
p,0.05. Data not shown: total distance (ANOVA, group p,0.0001;
post-hoc 12 vs. 30 mos, p,0.05): age difference within group, 4 vs.
12 mos., p,0.05; 22 vs. 30 mos., p.0.05, and movement velocity
(ANOVA, group p,0.005; post-hoc 12 vs. 30 mos., p.0.05): aging
difference within group, 4 vs. 12 mos., p,0.05; 22 vs. 30 mos., p,0.05.
doi:10.1371/journal.pone.0008466.g004
Figure 5. Individual locomotor activities with respect to group
throughout the life span. Young adult and old rats were tested at 4
and 22 months old, and again at 12 and 30 months old. There was a
significant correlation in locomotor activity between the mean
performance for each test subject at the first testing period (ten trial
average) and second testing period (seven trial average) of locomotor
activity tested eight months later: a. movement number, p,0.0001,
r=0.865; b. horizontal activity (HAC), p=0.0001, r=0.846; c. time spent
moving (as seconds per hour), p,0.0001, r=0.868. Data not shown are
movement speed (cm/sec), p=0.0001, r=0.848, and distance traveled
(cm/hr), p,0.0001, r=0.881.
doi:10.1371/journal.pone.0008466.g005
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8466affects locomotor activity measures. We found that DA levels were
significantly lower only in the SN (36% decrease including outlier
in 30-month group and 43% decrease without it (Fig. 6)). The
levels of DA between the 12 and 30 month old groups trended
lower in the striatum (15% decrease) and NAc (11% decrease),
but, like those in VTA, were not significantly different. Of note,
the nigral DA value in the outlier subject of the older group was at
the 12-month mean (8.3 ng/mg protein) and this subject had the
highest locomotor activity level of the group. Total DA levels (not
normalized to total protein) in SN also decreased significantly in
the 30 month group (Fig. S4). Therefore, the significant decrease
in overall DA bioavailability occurring in the 30 month group only
in the SN implies that ser31 phosphorylation is also decreased in
aged SN, given the importance of ser31 phosphorylation in
regulating DA bioavailability in intact neuropil (Figs. 1, 2).
3.5 The Role of TH in Locomotor Activity
Nigral TH protein content alone did not significantly correlate
to locomotor activity measures (data not shown). This was not
particularly surprising given the involvement of phosphorylation at
ser31 in regulating bioavailability of DA in the CNS (Figs. 1, 2).
There was a significant decrease in TH protein in the SN in the 30
month old group, when the previously mentioned outlier was
removed from this group (p,0.05) (Fig. 7a, b), consistent with
reports as discussed in the introduction. [The total TH protein in
this subject accounted for significantly elevated DA levels, as ser31
phosphorylation in this subject was only 14% above the group
mean.] No significant age-related loss of TH protein was seen in
the other three regions (data not shown). There was also a 30%
reduction in ser31 phosphorylation in the SN in the 30-month
group (p,0.05) (Fig. 8a,b) and, as a result of the lower TH protein
and ser31 phosphorylation, there was a 44% reduction in the
effective stoichiometry of ser31 (p,0.05) (data not shown). This
was identical to the actual decrease in DA levels in the SN (Fig. 6b).
Other than a ,20% reduction in ser19 phosphorylation in VTA
and ser31 phosphorylation in the NAc, no other significant aging-
related changes in phosphorylation were observed in the four
brain regions (data not shown).
Figure 6. Aging and DA tissue content. Values are ng DA/ mg protein in 12- and 30-month old subjects in the nigrostriatal (a, b) and
mesoaccumbens (c, d) dopaminergic pathways. a. striatum, ns, 12 mo.,178617, 30 mo., 152619, b. substantia nigra,* * p,0.01, 12 mo., 7.660.5, 30 mo.
4.960.6, c. nucleus accumbens, ns, 12 mo., 8366.9, 30 mo. 7462.8, d. ventral tegmental area, ns, 12 mo., 9.061.5, 30 mo., 9.462.5. These statistical
relationships (Student’s t-test, unpaired) also held in the comparison of total DA recovery (not normalized to protein) in each region (Fig S4).
doi:10.1371/journal.pone.0008466.g006
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field locomotor activity (Fig. 3) as well as the role of ser31 effective
stoichiometry in determining DA bioavailability (Figs. 1, 2), ser31
TH phosphorylation in SN would be predicted to correlate to
inherent locomotor activity. Indeed, ser31 phosphorylation was
correlated to the same locomotor activity measures as total DA or
DA normalized to protein (Table 1), with the only exceptions
being lowest lifetime total distance and lowest time spent moving
measures. Our longitudinal characterization of locomotor activity
enabled us to determine how effective stoichiometry of ser31 in SN
affected locomotor capabilities. There was a significant correlation
with the highest ever recorded lifetime movement number,
horizontal activity, and time spent moving (Fig. 9). Therefore,
nigral ser31 TH phosphorylation may regulate inherent abilities to
generate locomotor activity.
Discussion
Somatodendritic release of nigral DA has been long established
[34] and its pharmacological manipulation modulates locomotor-
regulating functions of the basal ganglia and aspects of locomotion
[39–41,59]. Furthermore, transplantation of mouse fetal midbrain
cells into the SN, rather than the striatum, of 6-OHDA-lesioned
adult mice may have a greater restorative capacity to locomotor
function [60]. Nonetheless, it has been questioned as to whether
such manipulations could somehow coincidentally modulate striatal
functions. Here we show, using intact and pharmacologically-naı ¨ve
rats with inherent differences in locomotor activity, that locomotor
activity generationcapacitiesinan open-field correlate to nigral,but
not striatal, DA tissue content. Furthermore, the aging-related loss
of DA in the SN, rather than striatum, in conjunction with a
significant decline in locomotor activity in the 30-month group
supports a role for nigral DA tissue content in modulating
locomotor activity generation. We note that movement speed was
not correlated with nigral DA tissue content and was also not
significantly different between the 12 and 30 month old subjects,
suggesting this component of locomotor activity is not influenced by
nigral DA content. Striatal and accumbal DA content do affect
motivational aspects oflocomotoractivity[31–32,61].However,the
lack of significant DA loss in striatum or nucleus accumbens
between the age groups may have accounted for why there was not
a significant correlation in these regions with locomotor speed.
Well-executed aging studies that quantify striatal DA show
varying amounts of tissue DA loss with age, ranging from 0 up to
,50% [11–15,17,44,54,62–65]. However, if the widely-accepted
threshold of 70–80% loss of DA neuropil is necessary for
appearance of PD motor symptoms (such as bradykinesia), we
must consider then how the lesser (if any in some cases) loss of
striatal DA in aging still precipitates bradykinesia. In PD models,
PD-like symptoms are not observed with 42–58% loss of striatal
DA [10]. It is possible that striatal DA is critical for aspects of
locomotor activity not related to initiating locomotor activity, such
as movement speed. However, the loss of nigral DA seen in our
work has also been reported in other aging studies [13,17,44].
Furthermore, loss of nigral TH protein of ,40%, as seen in the
30-month group in our study (Fig. 7), is coincident with PD-like
symptoms in PD models [10] and in human PD patients [42].
These observations in conjunction with our findings, which are
Figure 7. Nigral TH protein loss in aging. a. Representative blot showing the ,40% decrease in total TH (tTH) protein in the SN in a 30-month
old BNF rat compared to the tTH content in the 12-month old. All TH protein assays are conducted against a standard curve with quantified TH
protein. A specific quantity of total protein is loaded from the sample to determine the ng tTH per mg protein and the quantity from the sample is
interpolated from the standard curve. b. nigral total TH protein content between the 12- and 30-mo old subjects, 0.05360.010 and 0.02860.005 ng
per mg protein, respectively. p,0.05 (Student’s t-test, unpaired).
doi:10.1371/journal.pone.0008466.g007
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PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8466Figure 8. Nigral TH phosphorylation stoichiometry in aging. a. Representative blot showing the 30% decrease in TH phosphorylation at ser31
in the 30-month old BNF rat. All TH phosphorylation assays are conducted against a standard curve with quantified site-specific phosphorylation
levels so actual quantities of phosphorylated TH at each phosphorylation site are loaded in the standard curve range and the quantity of
phosphorylated TH from the sample is interpolated from the standard curve. Because actual quantities of total TH (tTH) vary from sample-to-sample,
it is not always possible to load equal amounts of tTH. Total protein load among samples is kept within 25 mg if at all possible to keep any carrier
protein effects upon the signal to an absolute minimum. In this case, total protein load differed by 10 mg (80 mg for the 12 mo sample and 90 mg for
the 30 mo sample). The standard curve source is from a calibrated PC12 cell extract with a phosphorylation stoichiometry at ser31 at 0.09 ng p31 per
ng tTH. b. Site-specific phosphorylation of TH in the SN in test subjects. The 30-month group had significantly reduced phosphorylation at ser 31
(p=0.029, unpaired Student’s t-test). No significant change was observed at ser40 or ser19.
doi:10.1371/journal.pone.0008466.g008
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PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e8466coincident measures of both striatal and nigral DA that are
associated with longitudinally-characterized locomotor activity,
make a case that nigral DA has a role in modulating basal ganglia
circuitry to facilitate the generation of locomotor activity.
Given that both the locomotor activity and DA and TH
analyses were conducted in the same rats, a critical importance for
phosphorylation at ser31 in regulating DA tissue content and a
DA-dependent behavior (locomotion) was revealed. First, the
differences in DA tissue content across the four regions did not
correspond to total TH protein (Fig. 1, a, b). However, in
conjunction with TH protein content, phosphorylation at ser31,
but not ser19 or ser40, showed significant differences between
striatum, SN, nucleus accumbens, and VTA that reflected the
inherent differences in DA tissue content in these regions (Fig. 1,
2). The other major indication that ser31 phosphorylation affected
DA bioavailability is that the significant loss of DA (along with TH
protein loss) in the SN in the aged subjects was associated with a
significant decrease in phosphorylation only at ser31. Together,
these observations address which TH phosphorylation site
regulates DA biosynthesis in vivo in intact neuropil: a vital question
yet to be answered. However, phosphorylation at ser40 can
increase DA biosynthesis [24–26]. It may that challenges to DA
systems such as that in neurodegenerative processes could increase
ser40 phosphorylation to an extent that affects DA biosynthesis
capabilities [27,28]. Still, in intact and drug-naı ¨ve DA pathways,
ser31 phosphorylation and TH protein levels appear to regulate
basal DA bioavailability. In the SN, these mechanisms may define
the maximal locomotor capabilities inherent to our test subjects
(Fig. 9). Determining whether ser31 or ser40 regulate DA
biosynthesis in the TH-depleted SN in a PD model is an
important next step, particularly since aging may impair
compensatory processes that normally replenish DA in the face
of TH loss seen in PD and PD models [65,66].
Our assessment of locomotion took into account that the
neurochemical profile attained for each test subject was only a
one-time measure. In spite of definite differences in average
locomotor activity shown in the test subjects, the test subjects had
variable locomotor activity from trial to trial (Fig. S5). Therefore, a
correlation of DA bioavailability with the 17
th and final trial was
essential. On one hand, this correlation might be expected to be
the most relevant one because the DA levels inherent in the test
subject were temporally matched with the locomotor activity
observed. On the other hand, indeterminate factors could also
influence locomotion on a trial to trial basis, such as the subject’s
level of arousal, motivation for food or drink, or circadian type
fluctuations that might occur within the 8 hour time window (0900
to 1700) we did our testing. Therefore, average locomotor activity
results would attenuate the influence of these indeterminate effects.
We found significant correlations with nigral DA content for all
comparisons to movement number, horizontal activity, and time
spent moving when accounting for these variables (Table 1). It is
also possible that trial-by-trial variances in locomotor activity
could be related to variances in DA bioavailability, which, like
locomotor activity, could fluctuate around a mean value. We also
point out that in the minority of observations in the 17 trials, there
were some matched test subjects that, in spite of having significant
differences in mean activity, had on occasion similar locomotor
activity (Fig. S5). This observation suggests that other aging-
related issues such as muscle function likely did not contribute to
the aging-related decline of locomotor activity generation. For if
aging-related muscle dysfunction did affect movement generation,
an older rat would presumably never generate movement akin to
that of a younger rat. The lack of correlation of central DA systems
with aging-related muscle function decline has also been
previously reported [67].
Aging brings an inherent risk of developing Parkinson’s-like
symptoms [3,4], and their incidence increases dramatically from
15% of those at age 65 to 52% at age 85 [4]. This suggests that
Figure 9. Effective stoichiometry at ser31 and locomotor
activity. Effective stoichiometry of ser31 (the product of ser31
phosphorylation stoichiometry and TH protein quantity) correlates
with the highest ever recorded locomotor activity measures (movement
number, horizontal activity, and time spent moving) of the 17 trials for
each test subject. Spearman correlation stats are as follows; move-
ment number (a), r=0.59, p=0.03, horizontal activity (b), r=0.65,
p=.01, time spent moving (c), r=0.57, p=0.03.
doi:10.1371/journal.pone.0008466.g009
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certainly increases with advancing age. The neurobiological basis
for the occurrence is not well understood. In our study, it appears
that activity levels, which may ultimately be related to nigral ser31
and TH protein levels, at a younger age dictate the locomotor
activity with advancing age (Fig. 5). There was a significant
decrease in locomotor activity parameters that correlated with
nigral DA (movement number, horizontal activity, and time spent
moving) between 22 and 30 months of age (Fig. 4). We did not
measure DA in the 22-month old rat, but there was a significant
decrease in nigral DA in the 30-month rat compared to the 12-
month old rat (Fig. 6). Based upon the locomotor data and the two
time points at 12 and 30 months wherein DA was measured, we
would predict that nigral DA loss would be less overall at 22
months than at 30 months. Taken together, these data imply that
the likelihood bradykinesia occurring with aging may depend
upon activity levels at a younger age, and nigral ser31
phosphorylation and TH protein levels could play a role in the
inherent risk of developing aging-related Parkinsonism.
In spite of little or no loss of striatal DA tissue content in the
aged test subjects, deficient DA release in aged striatum [12,14],
could impact locomotor activity. However, release capacity of
nigral DA also decreases to ,70% [14]. Therefore, both regions
show diminished DA release capacity with aging. Thus the
contribution of diminished DA release in either region to aging-
related bradykinesia is not known. However, pharmacological
blockade of nigral DA release to the extent seen in aging reduces
rotorod performance [39], which suggests sufficient nigral DA
bioavailability is necessary for enabling movements required to
negotiate motor tasks. We show nigral DA content in the 30-
month old group was ,4.3 ng/mg protein or 6.6 ng of total nigral
DA in the rostral-caudal extension and this was associated with
significant reduction in locomotor activity relative to adult, 12-
month old rat, which had ,7.6 ng/mg protein or 10.3 ng total
nigral DA. The significant correlation of nigral DA with locomotor
activity measures (Fig. 3, Table 1) and aging-related reductions in
nigral DA both make a case that nigral DA bioavailability is
involved with the generation of locomotor activity.
Striatal or accumbal DA content could influence aspects of
locomotion not related to its initiation and maintenance, such as
movement speed [30,61]. Notably, movement speed was not
significantly different between the two age groups and did not
correlate to nigral DA as did the other four parameters measured
(Table 1). Thus, movement speed may be independent of the
ability to initiate locomotor activity and is likely to be associated
with DA signaling in striatum or nucleus accumbens, wherein DA
signaling has been linked to motivational states [31,61,68]. We did
note a trend toward significance with lifetime and second session
average movement speed correlating to total striatal DA
recovered. Therefore, experimental manipulation of DA in these
regions beyond that produced by aging in this study (Fig. 6) could
reveal a role for DA in locomotor parameters affected in PD
(wherein such major loss is seen) such as movement speed,
balance, gait function, and tremor at rest. It must be noted,
however, that the inherent ability to generate movement, or
readiness, is likely to be associated with DA bioavailability of the
nigrostriatal pathway [69]. Our data suggest that nigral DA
bioavailability is a significant neurobiological component in
inherent abilities to initiate volitional movement.
In summary, longitudinally-characterized locomotor activity
patterns of pharmacologically-naı ¨ve rats with intact nigrostriatal
and mesoaccumbens pathways showed that nigral DA bioavail-
ability, as regulated by TH protein and phosphorylation at ser31,
influenced inherent capacities for the initiation and maintenance
of locomotor activity. Reduced nigral, but not striatal, DA was
associated with aging-related bradykinesia. We do not imply that
striatal or accumbal DA has no influence upon locomotor activity,
but it may be that experimental manipulation of DA levels
exceeding that seen in this study (15% or less DA loss) may be
necessary to determine how DA in these regions affects other
locomotor parameters. We also show that in intact dopaminergic
neuropil, the phosphorylation of TH at ser31, but not ser40, in
addition to TH protein, governs DA bioavailability. This is not to
say that ser40 phosphorylation could not influence DA biosyn-
thesis capabilities in vivo, as certain pathologies or conditions might
increase ser40 levels sufficiently enough to impact DA biosynthesis
in vivo [27,28]. However, TH protein and phosphorylation at ser31
in the SN was significantly correlated with DA tissue content and
with locomotor activity levels. Therefore, studies wherein the
regulation of the biosynthesis of DA or other catecholamines, like
norepinephrine, is called into question in vivo must include analysis
of ser31 phosphorylation dynamics. Future studies should address
the extent to which changes in ser31 and ser40 phosphorylation,
induced via experimental manipulation, affect DA biosynthesis
capacity in the regions studied herein. Furthermore, modulation of
DA bioavailability through inhibition or augmentation of levels in
striatum and SN would determine the extent to which DA in each
region modulates particular aspects of locomotor activity. In a
larger realm, these results also suggest that focusing on
neurotransmitter function solely at terminal fields is insufficient
to understand behavior. Clearly, regulation of neurotransmitter
function in somatodendritic regions must be considered as well.
Supporting Information
Text S1 Critical supporting information for manuscript.
Found at: doi:10.1371/journal.pone.0008466.s001 (0.03 MB
DOC)
Figure S1 Phosphorylation-state specificity of ser31 antibody
produced by 21st Century Biochemicals. Top row values are the
quantity of total TH assayed to generate the phosphorylation-state
specific immunoreactivity quantities for the ser31 phosphorylation
site on TH (as listed in the bottom row). The relative
stoichiometries of ser31 phosphorylation for the two sources used
were 0.8 for the group of three standards on the left (lanes 1–3)
and 0.09 for the group of three standards on the right (lanes 4–6).
Found at: doi:10.1371/journal.pone.0008466.s002 (0.04 MB TIF)
Figure S2 Correlation of total TH versus total DA in the
substantia nigra (SN). Spearman r=0.656, p=0.011. All data
points represent operationally-matched results from SN dissections
from the subjects used in this locomotor correlation study.
Found at: doi:10.1371/journal.pone.0008466.s003 (0.01 MB TIF)
Figure S3 Correlation of movement number with other
locomotor activity parameters. Data presented are means of
individual locomotor tests conducted at 4 and 22 months and
movement number correlated to horizontal activity (HAC)
(p,0.0001; r=0.982), total distance (cm/hr) (p,0.0001;
r=0.947), and time spent moving (p,0.0001; r=0.937). No
significant correlation of movement number to movement speed
(movt velocity) (p=0.065) was seen. Significant correlations were
also observed at 12 and 30 months of age for HAC, total distance,
and time spent moving.
Found at: doi:10.1371/journal.pone.0008466.s004 (0.01 MB TIF)
Figure S4 Dopamine content (expressed as total harvested in the
dissections) in the SN. In Figure 5 in the main text, DA content is
normalized to total protein. This figure shows that total DA tissue
content is reduced in the 30 month group, overall. Note there is
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PLoS ONE | www.plosone.org 13 December 2009 | Volume 4 | Issue 12 | e8466considerable overlap in nigral DA content between the two
groups, and the DA levels from each of these subjects were
compared to locomotor parameters, as seen in Table 1 in main
text and Table S2. Overall levels were 10.3060.96 ng in the 12-
mo group and 6.661.0 ng in the 30-mo group. Statistics,
Unpaired Student t-test p,0.05.
Found at: doi:10.1371/journal.pone.0008466.s005 (0.01 MB TIF)
Figure S5 Example of between-group differences and session-to-
session variability total distance and movement number in two
selected pairs of young and old test subjects. Test results are from
the 12 and 30 month session. In young-1 vs. old-1, no difference in
mean locomotor activity was seen in spite of the age difference,
whereas in young-2 vs. old-2 a significant difference in mean
locomotor activity is evident. This exception to the overall
difference in locomotion with aging we report highlights that
aging is not necessarily associated with bradykinesia on a case-by-
case basis. Furthermore it is evident that young-1 would be at the
low end of activity level for that age-group, when compared to
activity seen in young-2. Also noted in the young-2 versus old-2
comparison is that in order to fully characterize locomotor activity,
multiple sessions are necessary. For example, if comparing session
results from the young subject that were at the low end of the
locomotor activity range versus session results from the old subject
at the high end of the range, as highlighted by the box-inset, little
difference in locomotor activity between the subjects would be
concluded.
Found at: doi:10.1371/journal.pone.0008466.s006 (0.01 MB TIF)
Table S1 Habituation of locomotion.
Found at: doi:10.1371/journal.pone.0008466.s007 (0.04 MB
DOC)
Table S2 Mesoaccumbens pathway DA correlations (p-values).
Found at: doi:10.1371/journal.pone.0008466.s008 (0.05 MB
DOC)
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